That subset is the persistent, long-lived plasma cell. According to the review, these cells reside mostly in the bone marrow and have the potential to drive the chronicity of antibody-mediated diseases. Their longevity also underlies why such diseases can become refractory to classical therapeutic approaches, which are based on targeting ongoing immune reactions.

The distinction matters mechanistically. Therapies aimed at active immune responses can suppress newly generated antibody production, but long-lived plasma cells are maintained independently of continuous immune stimulation. As long as these cells survive, they can continue releasing antibodies without the inflammatory activity that conventional treatments are designed to interrupt.

A major focus of the review is the biology that keeps long-lived plasma cells alive. The authors discuss recent progress in identifying the critical extrinsic survival signals that these cells receive from their microenvironment, alongside the intrinsic signalling pathways operating within the cells themselves.

Importantly, the review emphasises that these survival mechanisms are not single, simple dependencies. The authors describe them as redundant, diverse and integrated, a combination that helps explain why eliminating pathogenic plasma cells has remained difficult and why blocking any one pathway in isolation may be insufficient.

A second theme is heterogeneity. Long-lived plasma cells are not presented as a uniform population: the review highlights their diversity across developmental origins, antibody isotypes and the tissues in which they reside, with their survival niches varying accordingly.

In the authors’ framing, this apparent diversity is not only an obstacle but also an opportunity. The heterogeneity of plasma cells and their niches may offer new options for selective therapeutic interventions, potentially allowing pathogenic subsets to be targeted while protective antibody production is preserved.

Building on this framework, the authors outline a spectrum of therapeutic strategies that is evolving for antibody-mediated diseases. It ranges from generic ablation of plasma cells, through more selective approaches that exploit differing survival dependencies, to the long-term goal of antigen-specific ablation, in which only the cells producing disease-causing antibodies would be removed.

The authors are careful about the status of these ideas. The review integrates recent findings on plasma cell survival biology into a conceptual framework, and the therapeutic strategies it describes remain a research outlook rather than validated clinical results. Its contribution lies in organising current knowledge about long-lived plasma cells into a roadmap for how more precise interventions might eventually be developed.

Subject of Research: The role of long-lived plasma cells in antibody-mediated diseases and emerging therapeutic strategies targeting them

Article Title: Plasma cells – a key target in antibody-mediated diseases

Article References: Fiebig, L., Alexander, T., Tokoyoda, K., Dörner, T., Mei, H. E., Hiepe, F., Mashreghi, M.-F., Hauser, A. E., Chang, H.-D., & Radbruch, A. (2026). Plasma cells – a key target in antibody-mediated diseases. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06496-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06496-4

Keywords: plasma cells, antibody-mediated diseases, immunology, bone marrow, humoral immunity, autoimmunity, therapeutic strategies, review article, Plasma, cells, target, antibody-mediated